Targeting the PERK/NRF2 pathway: Enhancing cisplatin efficacy in resistant ovarian cancer cells via MRP1 and ROS modulation
Food and Chemical Toxicology · 2025
DOI: 10.1016/j.fct.2025.115672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food and Chemical Toxicology, 2025. Verfasst von Seyedeh Sara Ghorbanhosseini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. Hauptthemen laut MEDLINE: Cisplatin, Ovarian Neoplasms, Drug Resistance, Neoplasm, Reactive Oxygen Species. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Isfahan University of Medical Sciences, Iran National Science Foundation, Mashhad University of Medical Sciences.
Abstract (Originalsprache)
Overcoming chemotherapy resistance remains a pivotal challenge in ovarian cancer treatment. This study investigates the potential of combining cisplatin with GSK2606414, a PERK inhibitor, to enhance therapeutic efficacy against cisplatin-resistant ovarian cancer cells. cisplatin resistance is driven by the PERK/NRF2 pathway, which activates MRP1 upregulation and antioxidant defenses, thus promoting cell survival. By inhibiting PERK phosphorylation, GSK2606414 disrupts this pathway, downregulating MRP1 and increasing oxidative stress to sensitize cancer cells to cisplatin. Our findings reveal that the GSK2606414-cisplatin combination significantly reduces cell viability and proliferation, particularly in resistant cell lines, allowing for dose reduction and potentially lower side effects. The combined therapy also amplifies, increasing Caspase-12 and CHOP protein levels during endoplasmic reticulum stress. By targeting the p-PERK/p-NRF2/MRP1 and p-PERK/p-NRF2/SOD pathways, GSK2606414 decreases MRP1 expression and elevates ROS levels, rendering resistant cells more susceptible to chemotherapy. Additionally, this combination boosts intracellular cisplatin accumulation in both cisplatin-sensitive and -resistant ovarian cancer cell lines, reinforcing its cytotoxic impact. These findings underscore the promise of GSK2606414 and cisplatin co-treatment as a potent strategy to counteract ovarian cancer resistance. This combination could potentially advance therapeutic outcomes and provide a new pharmacological approach to resistant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Clinical Biochemistry, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: maghaei@pharm.mui.ac.ir.
Förderung
- Isfahan University of Medical Sciences
- Iran National Science Foundation
- Mashhad University of Medical Sciences
Zitieren
APA
Ghorbanhosseini, S. S., Nourbakhsh, M., Mosaffa, F., & Aghaei, M. (2025). Targeting the PERK/NRF2 pathway: Enhancing cisplatin efficacy in resistant ovarian cancer cells via MRP1 and ROS modulation. Food and Chemical Toxicology. https://doi.org/10.1016/j.fct.2025.115672
Vancouver
Ghorbanhosseini SS, Nourbakhsh M, Mosaffa F, Aghaei M. Targeting the PERK/NRF2 pathway: Enhancing cisplatin efficacy in resistant ovarian cancer cells via MRP1 and ROS modulation. Food and Chemical Toxicology. 2025. doi:10.1016/j.fct.2025.115672
BibTeX
@article{Ghorbanhosseini2025,
author = {Ghorbanhosseini, Seyedeh Sara and Nourbakhsh, Mitra and Mosaffa, Fatemeh and Aghaei, Mahmoud},
title = {Targeting the PERK/NRF2 pathway: Enhancing cisplatin efficacy in resistant ovarian cancer cells via MRP1 and ROS modulation},
journal = {Food and Chemical Toxicology},
year = {2025},
doi = {10.1016/j.fct.2025.115672}
}
EUVIMED